← Back to signals
CAI
LONGINSIDER BUYCARIS LIFE SCIENCES INC
Funds
3
Score
4.50
vs SPY
-22.8%
Stock return (since Q-end)
-6.5%
SPY return (since Q-end)
+16.3%
Current price
$16.72
News Summary
PositiveCaris delivered strong Q1 2026 results with 79% YoY revenue growth, margin expansion to 65%, and net loss narrowing to $0.5M, while reaffirming full-year 2026 guidance of $1.0-1.02B. Key growth drivers include 85% YoY molecular profiling revenue growth, 61% clinical ASP increase, and new product launches (ChromoSeq with MolDX approval, MI Clarity), though sequential Q2 case volume growth expectations were reduced from 7% to 10% catch-up timing.
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | QoQ | Status |
|---|---|---|---|---|---|---|
| Coatue Management | Philippe Laffont | 9.8M | +9.8M | $175.6B | — | NEW |
| Point72 | Steve Cohen | 918K | +918K | $16.4B | — | NEW |
| Duquesne Family Office | Stanley Druckenmiller | 1.9M | +1.9M | $34M | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed |
|---|---|---|---|---|---|---|
| Vacirca Jeff L | — | BUY | 31K | $16.15 | $0.50M | 2026-05-11 |